Generic player Teva has won 180 days exclusivity for Losartan (Cozaar) and Losartan + HCTZ (Hyzaar) after Court of Appeals for District of Columbia Circuit overturned a lower court's decision that Teva had forfeited its exclusivity rights in the light of delisting of another Orange Book patent on polymorph by innovator Merck & patent assignee Du Pont.
The product patent on Losartan (Cozaar) and Losartan + HCTZ (Hyzaar) will expire on Apr 06, 2010. Now, other generic players will be able to launch this product after the expiry of Teva's 180 days exclusivity in Oct, 2010.
No comments:
Post a Comment